Journey Strategic Wealth LLC Has $340,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Journey Strategic Wealth LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 477 shares of the biopharmaceutical company’s stock after selling 202 shares during the period. Journey Strategic Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $340,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clearbridge Investments LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $1,506,000. Centaurus Financial Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $118,000. Czech National Bank boosted its position in Regeneron Pharmaceuticals by 7.0% during the 3rd quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock worth $22,725,000 after acquiring an additional 1,405 shares during the last quarter. Park Avenue Securities LLC grew its stake in shares of Regeneron Pharmaceuticals by 7.6% during the 3rd quarter. Park Avenue Securities LLC now owns 1,889 shares of the biopharmaceutical company’s stock worth $1,986,000 after acquiring an additional 134 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 32.6% in the third quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 353 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Bank of America reissued an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $672.98 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a fifty day simple moving average of $720.81 and a 200 day simple moving average of $922.87. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The company has a market capitalization of $73.95 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.